The sector has seen billions in merger and acquisition activity in recent years; a September 2024 analysis by Insight ...

Adding pembrolizumab to docetaxel did not significantly improve outcomes in previously treated patients with mCRPC.

The radiopharmaceutical lutetium 177 can be used after radium 223 to treat metastatic castration-resistant prostate cancer.

Pluvicto, a prostate cancer drug, has gained expanded approval that triples the number of patients with metastatic disease ...

After much delay, Novartis has finally won a key FDA go-ahead for Pluvicto, opening up the radioligand therapy to a much ...

The radioligand agent is now approved for use before chemotherapy in patients who have been treated with an androgen receptor ...

The FDA approved several therapies in oncology in the month of March 2025. These drugs included treatments for ...

The U.S. Food and Drug Administration (FDA) on Friday approved Novartis AG’s NVS Pluvicto for prostate cancer patients. The expanded indication, which approximately triples the number of patients ...

Janux Therapeutics' lead drug, JANX007, shows promising prostate cancer results with no serious side effects. Find out why ...

The antibody-drug conjugate FOR46 showed the strong potential of using CD46 as a new therapeutic target in metastatic ...

Novartis (NVS) announced that the Food and Drug Administration approved Pluvicto for patients with prostate-specific membrane antigen-positive ...

FDA expands Pluvicto indication to adults with PSMA+ metastatic castration-resistant prostate cancer previously treated with ...